The Articles of the American Rx
Bill of Rights
It is time
to call out the harmful effects of the undue influence of Pharma upon public
health policy. It is time for an Rx Bill of Rights on behalf of All
Americans
Article One (A Basic Right to Good Health)
The impact of millions of
Americans being denied the health benefits of access to a regimen of safe,
affordable medicines because of cost is a national health issue that has
yet-to-be-recognized consequences. That is why the ability of American
Citizens to make health care decisions in concert with their
physicians such as the purchase of personally imported safe, affordable
prescription medicines should not be hampered by any actions by government or
private entities as a policy to restrict Americans' access to authentic
medicines.
Article Two
(An Unaffordable Medicine is Unavailable)
A prescription medicine that is
unaffordable is unavailable, thereby meeting the 'rules' of the FDA that such a
medicine that is otherwise unavailable is indeed eligible to be personally
imported by an American patient, Arbitrary denial by the FDA to such access is
detrimental to the health of the patient by denying him or her access to
vital maintenance medicines. This is a violation of the purpose of the FDA
which is ostensibly designed to protect the health and well-being of American
citizens.
Article
Three (Citizens as Stakeholders)
The relationship between the
FDA, elected officials, and Pharma has led to numerous abuses, access by Pharma
to legislators and other elected officials based on the contribution of
millions of dollars, favored status for Pharma representatives and their front
groups as the primary representative at public hearings to determine the health
care policy for Federal, State and Local Governments, thereby skewering the
decision-making process. That why it is incumbent upon Congress that it
act to ensure that ordinary American citizens whose health and finances are
adversely affected by Pharma pricing practices, advocacy groups other than
those of Pharma, are given a 'stakeholder' status equal to that of Pharma.
Article
Four (Due Process)
Americans who purchase safe,
affordable medicines from licensed, registered pharmacies in Tier One Countries
whose standards meet or exceed those of the U.S., are the legitimate owners of
their authentic medicines and are entitled to exercise their due process rights
to have their personal property free from undue and unjustified seizure oar
destruction by any governmental agency unless the seizing authority can
demonstrate via established judicial processes and to courts that such seizures
are of bogus, counterfeit or unsafe prescription medicines.
Article
Five (Public Interest)
Americans are significant
contributors to the development of research and development costs of new
medicines through their tax dollars in support of grants to the National
Institutes of Health (NIH), and, as such, should be protected from unfair or
questionable patent protection granted to Pharma that fails to recognize the
rights of American citizens. Abuses in pricing, illegal business activities, or
undue influence upon policy-making by the FDA or elected officials should
result in a reduction of the patent protection afforded Pharma to the detriment
of untold numbers of Americans who must be able to pay what Pharma believes the
traffic will bear.
Article
Six (Reciprocity)
The FDA should extend
reciprocity to other Tier One countries in the interests of the health of
American citizens. The majority of brand name prescription medicines sold to
Americans is manufactured at plants outside the U.S., under FDA supervision, or
at plants licensed by Pharma members to produce medicines under a license granted
by a particular company, a validation that medicines produced outside the U.S.
and sold in this country are indeed capable of being safe. Also, the FDA
has entered into agreements with regulatory agencies in many countries to
assume the task of overseeing ingredients manufacture of ingredients for brand
name medicines. Added to that is that many countries (excluding the U.S
and the FDA) have reciprocal agreements (Memorandums of Understanding) that one
country will accept the medications produced in another country as safe and
authentic.
The impact of millions of
Americans being denied the health benefits of access to a regimen of safe,
affordable medicines because of cost is a national health issue that has
yet-to-be-recognized consequences. That is why the ability of American
Citizens to make health care decisions in concert with their
physicians such as the purchase of personally imported safe, affordable
prescription medicines should not be hampered by any actions by government or
private entities as a policy to restrict Americans' access to authentic
medicines. 
A prescription medicine that is
unaffordable is unavailable, thereby meeting the 'rules' of the FDA that such a
medicine that is otherwise unavailable is indeed eligible to be personally
imported by an American patient, Arbitrary denial by the FDA to such access is
detrimental to the health of the patient by denying him or her access to
vital maintenance medicines. This is a violation of the purpose of the FDA
which is ostensibly designed to protect the health and well-being of American
citizens.
The relationship between the
FDA, elected officials, and Pharma has led to numerous abuses, access by Pharma
to legislators and other elected officials based on the contribution of
millions of dollars, favored status for Pharma representatives and their front
groups as the primary representative at public hearings to determine the health
care policy for Federal, State and Local Governments, thereby skewering the
decision-making process. That why it is incumbent upon Congress that it
act to ensure that ordinary American citizens whose health and finances are
adversely affected by Pharma pricing practices, advocacy groups other than
those of Pharma, are given a 'stakeholder' status equal to that of Pharma.
Americans are significant
contributors to the development of research and development costs of new
medicines through their tax dollars in support of grants to the National
Institutes of Health (NIH), and, as such, should be protected from unfair or
questionable patent protection granted to Pharma that fails to recognize the
rights of American citizens. Abuses in pricing, illegal business activities, or
undue influence upon policy-making by the FDA or elected officials should
result in a reduction of the patent protection afforded Pharma to the detriment
of untold numbers of Americans who must be able to pay what Pharma believes the
traffic will bear.
The FDA should extend
reciprocity to other Tier One countries in the interests of the health of
American citizens. The majority of brand name prescription medicines sold to
Americans is manufactured at plants outside the U.S., under FDA supervision, or
at plants licensed by Pharma members to produce medicines under a license granted
by a particular company, a validation that medicines produced outside the U.S.
and sold in this country are indeed capable of being safe. Also, the FDA
has entered into agreements with regulatory agencies in many countries to
assume the task of overseeing ingredients manufacture of ingredients for brand
name medicines. Added to that is that many countries (excluding the U.S
and the FDA) have reciprocal agreements (Memorandums of Understanding) that one
country will accept the medications produced in another country as safe and
authentic.
Americans who purchase safe,
affordable medicines from licensed, registered pharmacies in Tier One Countries
whose standards meet or exceed those of the U.S., are the legitimate owners of
their authentic medicines and are entitled to exercise their due process rights
to have their personal property free from undue and unjustified seizure oar
destruction by any governmental agency unless the seizing authority can
demonstrate via established judicial processes and to courts that such seizures
are of bogus, counterfeit or unsafe prescription medicines.
No comments:
Post a Comment